Nordicnanovector
https://www.nordicnanovector.comNordic Nanovector’s lead clinical-stage candidate is Betalutin ®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the treatment of non-Hodgkin’s Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 26 billion in 2028.